Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The objective of this multicentric Phase III study is to confirm the results of the phase
I-II study (Dreno B & Al. Cancer Immunol Immunother 2002; 51: 539-456) which demonstrated the
preventive effect of a treatment by TIL (Tumor Infiltrating Lymphocytes) combined with IL2
(Interleukin 2; low dose injected subcutaneously) on the metastatic relapse in the stage III
melanoma patients with only one invaded lymphnode.